Rodrigo Merino, MD
Neurology · Albuquerque, NMNPI 1124127139
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,431 of the $3,290 with a category attached, or 73.9%. MDD US Operations, LLC accounts for 75.6% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $2,476 and has fallen 95.9% since, to $102 in 2025.
Across 31 payments — averaging $106.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MDD US Operations, LLC$2K
- AstraZeneca$361
- AbbVie$207
- Neurocrine Biosciences, Inc.$85
- Novartis$45
- Merz Pharmaceuticals, LLC$25
- plus $79 from 4 others
What the payments were for
- Travel & lodging$2,43174%
- Food & beverage$85826%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MDD US Operations, LLC | 13 | $2,489 |
| AstraZeneca | 3 | $361 |
| AbbVie | 7 | $207 |
| Neurocrine Biosciences, Inc. | 1 | $85 |
| Novartis | 2 | $45 |
| Merz Pharmaceuticals, LLC | 1 | $25 |
| Johnson & Johnson | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| Amgen | 1 | $19 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,290 in reported general payments places this provider in the 75th percentile of 91 neurology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 108 | $4,482 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 29 | $1,981 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 70 | $1,554 |
| Memantine Hcl | 61 | $1,274 |
| Lacosamide | 12 | $1,162 |
| Primidone | 34 | $564 |
| Donepezil Hcl | 58 | $552 |
| Teriflunomide | 13 | $493 |
| AmantadineAmantadine Hcl | 11 | $453 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 29 | $326 |
| Sumatriptan Succinate | 27 | $271 |
| Benztropine Mesylate | 13 | $230 |
| Topiramate | 29 | $158 |
Paid to pharmacies, not to this prescriber.
Other neurology in Albuquerque
- Elaine EdmondsAlbuquerque$610K
- Kader AbdelerahmanAlbuquerque$607K
- Timothy OwnbeyAlbuquerque$90K
- Gerson Suarez CedenoAlbuquerque$44K
- Corey FordAlbuquerque$27K
- Diksha MohantyAlbuquerque$20K
- Douglas BarrettAlbuquerque$19K
- Vanessa Licona SanjuanAlbuquerque$16K
- Daniel ShibuyaAlbuquerque$13K
- Alfred van BaakAlbuquerque$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.